Results 11 to 20 of about 37,133 (255)

Intrathoracic synovial sarcoma with BRAF V600E mutation. [PDF]

Oncotarget, 2023
We report a case of 15-year-old boy with intrathoracic synovial sarcoma who relapsed after standard chemotherapy, surgery and radiotherapy. The molecular analysis of the tumour identified a BRAF V600E mutation at time of progression of relapsed disease under third line systemic treatment.
Russo I, Barresi S, Di Paolo PL, Di Ruscio V, Del Baldo G, Serra A, Vallese S, Miele E, Mastronuzzi A, Alaggio R, Ferrari A, Milano GM.   +11 more
europepmc   +4 more sources

Clinical Images: Erdheim-Chester disease presenting with fever, enlarged lymph nodes, and monoallelic BRAF (V600E) mutation. [PDF]

ACR Open Rheumatol
ACR Open Rheumatology, Volume 8, Issue 3, March 2026.
Gan L, Zhang Q, Yan H, Bai H, Tang X.
europepmc   +2 more sources

BRAF V600E Inhibitor (Vemurafenib) for BRAF V600E Mutated Low Grade Gliomas [PDF]

Frontiers in Oncology, 2018
Low-grade gliomas (LGG) are the most common central nervous system tumors in children. Prognosis depends on complete surgical resection. For patients not amenable of gross total resection (GTR) new approaches are needed. The BRAF mutation V600E is critical for the pathogenesis of pediatric gliomas and specific inhibitors of the mutated protein, such as
Francesca Del Bufalo, Giulia Ceglie, Antonella Cacchione, Iside Alessi, Giovanna Stefania Colafati, Andrea Carai, Francesca Diomedi-Camassei, Emmanuel De Billy, Emanuele Agolini, Angela Mastronuzzi, Franco Locatelli, Franco Locatelli   +11 more
openaire   +3 more sources

Phase Ib study of anlotinib combined with TQB2450 in pretreated advanced biliary tract cancer and biomarker analysis

Hepatology, EarlyView., 2022
Phase 1b study of anlotinib combined with TQB2450 in pretreated advanced biliary tract cancer and biomarker analysis. Abstract Background and Aims We evaluated the efficacy and safety of the antiangiogenic tyrosine kinase inhibitor anlotinib plus TQB2450, a programmed death‐ligand 1 inhibitor in pretreated advanced biliary tract cancers (BTCs ...
Jun Zhou, Yongkun Sun, Wen Zhang, Jiajia Yuan, Zhi Peng, Wei Wang, Jifang Gong, Lin Yang, Yanshuo Cao, Hong Zhao, Chao Chen, Weifeng Wang, Lin Shen, Aiping Zhou   +13 more
wiley   +1 more source

High frequency of KRAS and EGFR mutation profiles in BRAF-negative thyroid carcinomas in Indonesia

BMC Research Notes, 2022
Objective Thyroid cancer incidence has steadily increased in Indonesia. However, data on Kirsten rat sarcoma virus (KRAS) and EGFR mutations in thyroid cancer in Indonesia remain unavailable, except for BRAF-V600E, the most common BRAF gene mutation ...
Didik Setyo Heriyanto, Vincent Laiman, Nikko Vanda Limantara, Widyan Putra Anantawikrama, Fara Silvia Yuliani, Rita Cempaka, Sumadi Lukman Anwar   +6 more
doaj   +1 more source

Utility of BRAF V600E Mutation-Specific Immunohistochemistry in DetectingBRAFV600E-Mutated Gastrointestinal Stromal Tumors [PDF]

American Journal of Clinical Pathology, 2015
As patients with BRAF V600E mutation respond to BRAF inhibitors, it is important to identify these mutations to stratify patients for the appropriate therapy. In this study, we evaluated the utility of a BRAF V600E allele-specific antibody in gastrointestinal stromal tumors (GISTs).BRAF V600E mutation-specific immunohistochemistry (negative, weak, or ...
Deepa T, Patil, Shuang, Ma, Mai, Konishi, Paula D, Carver, Marina, Pukay, Carol, Beadling, Christopher L, Corless, Brian P, Rubin   +7 more
openaire   +2 more sources

BRAFV600E Mutation and Papillary Thyroid Cancer [PDF]

JAMA, 2013
To the Editor Our recent multicenter study1 reported an association between BRAF V600E and PTC-related patient mortality. However, this association was not independent of tumor behaviors and the prognostic value of BRAF V600E was debated in an accompanying Editorial.2 This issue warrants further discussion in several aspects.
Alessia, Ciarrocchi, Silvio, Cavuto, Simonetta, Piana   +2 more
openaire   +4 more sources

BRAF V600E and lymph node metastases in papillary thyroid cancer

Endocrine Connections, 2020
Objective: To evaluate the relationship between the BRAF V600E mutation in lymph node metastasis (LNM) and its invasive characteristics in papillary thyroid cancer (PTC).
Pan Chen, Liqin Pan, Wensi Huang, Huijuan Feng, Wei Ouyang, Juqing Wu, Jing Wang, Yuying Deng, Jiaxin Luo, Yanying Chen   +9 more
doaj   +1 more source

Adult classical glioblastoma with a BRAF V600E mutation [PDF]

World Journal of Surgical Oncology, 2015
The B-Raf proto-oncogene serine/threonine kinase (B-Raf) is a member of the Raf kinase family. The BRAF V600E mutation occurs frequently in certain brain tumors such as pleomorphic xanthoastrocytoma, ganglioglioma, and pilocytic astrocytoma, and less frequently in epithelioid and giant cell glioblastoma.
Takahashi, Yoshinobu, Akahane, Toshiaki, Sawada, Takahiro, Ikeda, Hidetoshi, Tempaku, Akira, Yamauchi, Shigeru, Nishihara, Hiroshi, Tanaka, Shinya, Nitta, Kazumi, Ide, Wataru, Hashimoto, Ikuo, Kamada, Hajime   +11 more
openaire   +2 more sources

False-negative BRAF V600E mutation results on fine-needle aspiration cytology of papillary thyroid carcinoma

World Journal of Surgical Oncology, 2017
Background The BRAF V600E mutation is highly specific for papillary thyroid carcinoma (PTC). A test for this mutation can increase the diagnostic accuracy of fine-needle aspiration cytology (FNAC), but a considerably high false-negative rate for the BRAF
Se Hyun Paek, Byung Seup Kim, Kyung Ho Kang, Hee Sung Kim   +3 more
doaj   +1 more source